Clinical Trial Update: A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update for two IL-23/IL-12 inhibitors (ustekinumab and guselkumab) in pediatric participants with active juvenile psoriatic arthritis; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Psoriatic Arthritis

Drugs mentioned

• Stelara (ustekinumab)
• TREMFYA (guselkumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Arthritis, Juvenile | Phase 3 | Status: ACTIVE_NOT_RECRUITING